Daniel A Norris
Overview
Explore the profile of Daniel A Norris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gao X, Diep J, Norris D, Yu R, Geary R
Expert Opin Drug Metab Toxicol
. 2023 Nov;
19(12):979-990.
PMID: 37970635
Introduction: Advances in research and development (R&D) have enabled many approvals of antisense oligonucleotides (ASOs). Its administration expanded from systemic to local for treating various diseases, where predicting target tissue...
2.
Mummery C, Borjesson-Hanson A, Blackburn D, Vijverberg E, De Deyn P, Ducharme S, et al.
Nat Med
. 2023 Oct;
30(1):304.
PMID: 37845513
No abstract available.
3.
Yamamoto Y, Sanwald Ducray P, Bjornsson M, Smart K, Grimsey P, Vatakuti S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 May;
12(9):1213-1226.
PMID: 37221972
Tominersen is an intrathecally administered antisense oligonucleotide targeting huntingtin mRNA which leads to a dose-dependent, reversible lowering of cerebrospinal fluid (CSF) mutant huntingtin protein concentration in individuals with Huntington's disease....
4.
Mummery C, Borjesson-Hanson A, Blackburn D, Vijverberg E, De Deyn P, Ducharme S, et al.
Nat Med
. 2023 Apr;
29(6):1437-1447.
PMID: 37095250
Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting...
5.
Thornton C, Moxley 3rd R, Eichinger K, Heatwole C, Mignon L, Arnold W, et al.
Lancet Neurol
. 2023 Feb;
22(3):218-228.
PMID: 36804094
Background: Myotonic dystrophy type 1 results from an RNA gain-of-function mutation, in which DM1 protein kinase (DMPK) transcripts carrying expanded trinucleotide repeats exert deleterious effects. Antisense oligonucleotides (ASOs) provide a...
6.
Jafar-Nejad P, Powers B, Soriano A, Zhao H, Norris D, Matson J, et al.
Nucleic Acids Res
. 2020 Dec;
49(2):657-673.
PMID: 33367834
Antisense oligonucleotides (ASOs) have emerged as a new class of drugs to treat a wide range of diseases, including neurological indications. Spinraza, an ASO that modulates splicing of SMN2 RNA,...
7.
Norris D, Post N, Yu R, Greenlee S, Wang Y
Bioanalysis
. 2019 Oct;
11(21):1909-1912.
PMID: 31648523
No abstract available.
8.
Ramos D, dYdewalle C, Gabbeta V, Dakka A, Klein S, Norris D, et al.
J Clin Invest
. 2019 Oct;
129(11):4817-4831.
PMID: 31589162
BACKGROUNDSpinal muscular atrophy (SMA) is caused by deficient expression of survival motor neuron (SMN) protein. New SMN-enhancing therapeutics are associated with variable clinical benefits. Limited knowledge of baseline and drug-induced...
9.
Tabrizi S, Leavitt B, Landwehrmeyer G, Wild E, Saft C, Barker R, et al.
N Engl J Med
. 2019 May;
380(24):2307-2316.
PMID: 31059641
Background: Huntington's disease is an autosomal-dominant neurodegenerative disease caused by CAG trinucleotide repeat expansion in , resulting in a mutant huntingtin protein. IONIS-HTT (hereafter, HTT) is an antisense oligonucleotide designed...
10.
Welink J, Xu Y, Yang E, Wilson A, Henderson N, Luo L, et al.
Bioanalysis
. 2018 Nov;
10(22):1781-1801.
PMID: 30488725
The 2018 12 Workshop on Recent Issues in Bioanalysis (12th WRIB) took place in Philadelphia, PA, USA on April 9-13, 2018 with an attendance of over 900 representatives from pharmaceutical/biopharmaceutical...